Theracule is developing a new turmeric oil-derived therapeutic for the treatment of drug-refractory childhood epilepsy.
The main compound, TCA-01, is sourced from the turmeric root, and designed to provide an alternative for patients currently refractory to classical epilepsy medications. TCA-01 is enriched to contain 90% turmerones (small, drug-like molecules not related to curcuminoids).
Theracule has proprietary IP for the use of turmeric oil and individual turmerones as treatments for epilepsy
issued in the US, Europe and Japan.
Important Market Drivers are to aid in development and commercialization of TCA-01:
• Established regulatory pathway
• Orphan drug status (granting 7-10 years market exclusivity)
• 12+ orphan syndromes to be treated
• Strong patient advocacy
• Growing numbers of diagnosed patients